Results: Of all patients operated for rectal cancer, 27.4% received an intensified neoadjuvant treatment. Tumor location in the matched patients were in the lower third (55.2%), middle third (41.0 ...

Radiation dose intensification improves pathologic complete response rates in locally advanced rectal cancer but also leads ...

Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized ... The mention of any product, ...

A "watch and wait" strategy after total neoadjuvant therapy showed similar outcomes and safety to total mesorectal in stage ...

Patients with non-metastatic GIST treated with neoadjuvant TKIs prior to surgery experienced a benefit which led to less ...

Fifty percent of patients with both rectal and colon cancer had received neoadjuvant therapy. “Low-dose aspirin to reduce recurrence rate in colorectal cancer patients with PI3K pathway alterations: 3 ...

In an era dominated by pricey, high-tech drugs, the humble aspirin had a practice-changing impact on colorectal cancer (CRC) recurrence, according to a randomized study reported here. Patients with ...

They suggest new immunotherapeutic treatment strategies and highlight ... 2024.105228 Umair Mahmood et al, Stratification to Neoadjuvant Radiotherapy in Rectal Cancer by Regimen and ...

Dr Zaheer Mangera discusses the evolution of the neoadjuvant lung cancer pathway and notable changes to the TNM standards.

Data from five presentations underscore the transformative potential of BOT/BAL across multiple lines of therapy in colorectal cancer, including neoadjuvant, first-line, and refractory settings.

Reply to: Should Total Neoadjuvant Therapy Be the First-Line Treatment for Patients With Locally Advanced Rectal Cancer? The following represents disclosure information provided by authors of this ...

"Data presented at ASCO GI highlight botensilimab and balstilimab’s potential to redefine colorectal cancer treatment, delivering remarkable outcomes in neoadjuvant MSS CRC," said Dr. Steven O ...